Mustang Bio
Presence
Fortress Biotech is a company listed under the stock ticker FBIO (US).
Fortress Biotech has 4 subsidiaries including Avenue Therapeutics, Checkpoint Therapeutics and Journey Medical Corp.
They are in:
- Biotechnology80%
- Pharmaceuticals20%
Executives
View the org chart displaying its 16 main executives
Most searched biographies at Mustang Bio
- Manny Litchman, President, Chief Executive Officer and Director
- Michael Zelefsky, Director
- Adam Chill, Director
Create your alert
to follow the executive moves at Mustang Bio.
Biotechnology
Fortress Biotech has 2,279 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on April 18 2024).
Popular contacts in Biotechnology
News
Press releases by Mustang Bio
- Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
- Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
- Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
- Press Releases
- Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
- Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
- Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting
- Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma
- Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- View more press releases Close
Social media about Mustang Bio
- Mustang Bio on Wikipedia, Google News & Yahoo Finance
- Mustang Bio on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Greg Furrow 
